Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ: DTIL )

4.725 +0.225 (+5.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 170,262
Open 4.500
Bid (Size) 4.500 (1)
Ask (Size) 5.000 (5)
Prev. Close 4.500
Today's Range 4.490 - 4.840
52wk Range 4.130 - 19.43
Shares Outstanding 113,793,338
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming November Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire

Performance

YTD
-57.43%
-57.43%
1 Month
-31.12%
-31.12%
3 Month
-48.13%
-48.13%
6 Month
-49.84%
-49.84%
1 Year
-56.38%
-56.38%

More News

Read More
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
From Precision BioSciences
Via Business Wire
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter Results on November 4, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming August Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Second Quarter Results on August 1, 2024
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces its Addition to the Russell Microcap® Index
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
From Precision BioSciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.